Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Meiji Pharma Pursuing Low-Cost Strategy to Weather Storm in Generics Space, Overseas Plants Hold Key
March 11, 2019
- Japan Ethical Drug Sales Up 3.3% in January: Crecon
March 11, 2019
- CMIC CMO, Aprecia Join Hands for 3D Printing Therapies
March 11, 2019
- Eisai CEO Says “20% ROE in 2025” within Reach If All 3 Alzheimer’s Candidates, Lenvima Deliver
March 8, 2019
- Shionogi Bags Japan/Taiwan Rights to Akili’s Digital Medicines for ADHD, Autism
March 8, 2019
- Avastin Top Seller in Japan in February: Encise Snapshot
March 8, 2019
- Mitsubishi Tanabe’s Rupafin Most Promoted Drug in December: Anterio
March 8, 2019
- Eisai Seeks Japan Approval for Insomnia Med Lemborexant
March 8, 2019
- Toa Confident in Ensuring Stable Supply of Symbicort Generic with Expertise in Dry Powder Inhaler Manufacturing
March 8, 2019
- Teva Takeda Discloses Info on Producing Countries of Its Generic APIs
March 7, 2019
- Sawai’s Generic Abilify Approved for Depression
March 7, 2019
- Xofluza Filed in US to Treat Patients at High Risk of Flu-Related Complications: Shionogi
March 7, 2019
- Japan’s 1st Drug to Reduce Alcohol Consumption Launched: Otsuka
March 6, 2019
- Alcon Pharma to Be Integrated into Novartis Japan in April
March 6, 2019
- Bayer Submits Prostate Cancer Drug Darolutamide in Japan
March 6, 2019
- Pfizer Japan Logs 2.6% Growth in FY2018, No Job Cut Planned: Chief
March 6, 2019
- Sawai Recalls GI Drug after Doping Substance Found
March 6, 2019
- Fujifilm, Tokyo Medical and Dental Univ. Ink Regenerative Medicine Pact for Meniscal Injury
March 6, 2019
- Osteoporosis Drug Evenity Now Available: Amgen Astellas
March 5, 2019
- ASKA to Relocate Kawasaki Research Center to Shonan iPark; 1st Non-Takeda Pharma Tenant
March 5, 2019
ページ
Chugai Pharmaceutical’s Duchenne muscular dystrophy (DMD) gene therapy Elevidys has finally reached the Japanese market after months of safety reviews…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…